Other
Hypofractionated Radiotherapy
0
Pipeline Programs↗
9
Active Trials↗
1
Companies Involved↗
Hypofractionated Radiotherapy is an early-stage landscape with 0 programs across 1 company. The most active players are Manni Huang.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
17
clinical trials
Recruiting7 · 41%
Unknown status5 · 29%
Completed2 · 12%
Not yet recruiting2 · 12%
Withdrawn1 · 6%
Clinical Trials
Trial Activity
17 trials
Iparomlimab and Tuvonralimab Plus Hypofractionated Radiotherapy and Chemotherapy for HAHNSCC
Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 2·NCT07447570·27 enrolled
Adjuvant Moderately Hypofractionated Intensity-modulated Radiotherapy for Postoperative Cervical Cancer (AMICA-CC) : a Prospective, Multicenter, Phase II Trial
Recruiting·—·Preclinical·NCT07684508·154 enrolled
Hypofractionated Radiotherapy Followed by Chemo-immunotherapy Induction Therapy
Not yet recruiting·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT06914050·30 enrolled
RADVAX: A Stratified Phase I Trial of Pembrolizumab With Hypofractionated Radiotherapy in Patients With Advanced and Metastatic Cancers
Completed·—·Phase 1·NCT02303990·59 enrolled
Hypofractionated Radiotherapy and Concurrent Cisplatin for Head and Neck Cancer
Unknown status·—·N/A·NCT03194061·20 enrolled
Page 1 of 2
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)